

GRANT AGREEMENT

Parties to this agreement:

Diabetesforeningen

Att: Tanja Thybo
 Stationsparken 24, st.tv.
 2600 Glostrup
 CVR: 35 23 15 28
 (“Recipient”)

Novo Nordisk Denmark A/S

Att.: Tina Damgaard
 Kay Fiskers Plads 10, 7 floor
 2300 København S
 CVR No. 38180045

(“Novo Nordisk”)

1. Summary

- 1.1 Recipient’s request for support.** The appendix titled “Recipient’s request for support” details the specifics of the Recipient’s activity(ies) (“the Activity”) supported by the grant and purpose of the Activity. Novo Nordisk has decided to support the recipient’s request as part of its commitment to advance healthcare and science.

Title of Activity	Financial support for further development of “Diabetestal.nu”
Purpose of the Activity	The recipient shall use the grant only for the healthcare-related purpose of further developing “Diabetestal.nu” <i>The recipient’s purpose must not involve promotion of any pharmaceutical product.</i>
Grant amount	Novo Nordisk will provide 150.000 DKK including added tax if applicable, to support the Recipient’s request. Novo Nordisk will not make any non-financial transfers of value.
Agreement Duration	This agreement starts on 1/12/2024 and expires after all obligations are fulfilled, unless terminated earlier.

2. Recipient’s Duties

- 2.1 Compliance with law and ethics.** The Recipient shall comply with all applicable laws, rules, regulations, and professional standards, including those related to ethical business practices, bribery and corruption, among others. The Recipient will hold Novo Nordisk harmless against any claim or suit that arises in relation to any deviation from the above mentioned that is not due to any act or omission by Novo Nordisk.

- 2.2 Carry out the Activity with proper conduct.** The Recipient shall carry out the Activity independently and without Novo Nordisk influence, and in compliance with Novo Nordisk standards and industry codes such as IFPMA and EFPIA. Such proper conduct of the Activity includes, but is not limited to:

No use of funds for entertainment	Do not use the grant for leisure or social activities
No use of product names	Do not use trade and advertising names of medicinal products in any content or materials used for the Activity
Select qualified participants	Apply appropriate criteria to select participants in the Activity, including that any speakers, facilitators, and chairpersons are experts in the professional fields relevant to the Activity
Reasonable payment	If grant is used to provide payments to third parties, apply a reasonable rate, including following Fair Market Value for any payments to Healthcare Professionals (hereinafter refer to as ‘HCPs’) and patients

Grant Agreement, DK, 2022-DEC

Local Adaptation of HQ Grant Agreement v2
 July 2021

Reasonable choice of venue	Hold activities in a location suitable for business meetings with modest hospitality
Reasonable travel	If grant is used for Activity-related travel, carry out within reasonable time and cost

- 2.3 Internal approvals.** The Recipient shall obtain all necessary approvals related to the receipt of the grant.
- 2.4 Provide documentation within 1 month.** The Recipient shall provide Novo Nordisk with documentation that the grant was used for its intended purpose, within 1 month of completion of the Activity. Novo Nordisk may request additional detailed documentation as needed.
- 2.5 Inform Novo Nordisk of changes.** The Recipient shall inform Novo Nordisk of any changes affecting the request for support. Novo Nordisk may increase, decrease, withdraw or require full or partial repayment of the grant as a result of the changes. In the case of repayment, the Recipient shall refund Novo Nordisk the requested amount within 14 days.
- 2.6 Refund unspent amounts.** The Recipient shall refund Novo Nordisk any amounts not spent for the requested purposes, within 14 days after complete documentation of the Activity is provided.
- 2.7 Disclose Novo Nordisk as grant provider.** The Recipient shall mention Novo Nordisk as the provider of the grant in educational materials developed through the grant, as well as in any public communications or advertising related to the Activity.
- 2.8 Required public disclosures.** Novo Nordisk will publish information relating to this grant on Novo Nordisk's website (www.novonordisk.dk). According to Danish regulation Novo Nordisk may in addition make this Grant Agreement publicly available. The Recipient shall provide to Novo Nordisk upon request all information reasonably required for Novo Nordisk's compliance with legal and/or regulatory requirements for contracting, tracking and disclosing transfer of values (ToVs) to the Recipient.
- The Recipient will publish information on the grant on the Recipient's webpage. The information includes the grants amount and, if applicable, any in kind transfer, cf. the Danish Pharmaceutical Promotional Act (Reklamebekendtgørelsen) § 21. The information must be available on the Recipient's webpage no later than one (1) month after the Recipient received the Grant. The information must be publicly available for at least two (2) years.
- 2.9 Do not use Novo Nordisk branding without approval.** The Recipient may not use Novo Nordisk's logo, trademarks or other corporate identity marks or materials without written approval of the use from Novo Nordisk.
- 2.10 Allow Novo Nordisk to use Recipient's logo.** The Recipient permits Novo Nordisk to use the Recipient's logo, trademarks or other corporate identity marks in any public communications or advertising related to Novo Nordisk's grant.

3. Payment and Invoice Requirements

3.1 Payment after receipt of invoice. Novo Nordisk will send payment after receipt of invoice to the Recipient's bank account via electronic transfer within 30 days of receiving a complete invoice. Send completed PDF invoice to: AP-Novo-Repas@novonordisk.com. Include the below information on the invoice:

- Recipient name and address
- Bank account for electronic payment: Account holder name, account number (IBAN), bank name and address, routing number or code (SWIFT/BIC in EU, ABA/ACH in USA)
- Date of invoice
- The Title of Activity and dates of activities covered by the invoice
- Grant amount payable
- VAT or other tax amount payable (include separately from payment amount)
- Name of Novo Nordisk entity and address as stated in the introduction of this Agreement
- Novo Nordisk recipient of invoice as included below:

Name of Novo Nordisk invoice recipient Benedicte Rigmor Schiersing (BCRS@novonordisk.com)

4. Other Terms and Conditions

Grant Agreement, DK, 2022-DEC
Local Adaptation of HQ Grant Agreement v2
July 2021

- 4.1 Disclosure of Transfers of Value.** To comply with applicable transparency requirements, Novo Nordisk will collect and may disclose personal information, transfers of value and details of its payment to Healthcare Professionals (“HCPs”) and Healthcare Organizations (“HCOs”). In addition to the payment amount, such disclosure may also include: Name, address, contact details, nature of relationship with Novo Nordisk, tax number or unique identifier.
- 4.2 No conflict of interest.** Recipient states it is not aware of any conflict of interest related to its acceptance of the grant and shall promptly inform Novo Nordisk if such conflict of interest is discovered.
- 4.3 Compliance hotline.** The Recipient can report suspected misconduct through the Novo Nordisk compliance hotline. Information about using the hotline and examples of what to report can be found at [Report suspected misconduct \(novonordisk.com\)](https://www.novonordisk.com/report-suspected-misconduct).
- 4.4 No incentive to prescribe or recommend.** The payments made by Novo Nordisk indicate no incentive or obligation for the Recipient to prescribe, recommend or otherwise support Novo Nordisk’s products or services.
- 4.5 Termination for breach.** Either party may terminate this contract immediately upon material breach by the other party.
- 4.6 Governing Law and Dispute Resolution.** The laws of Denmark govern this agreement, disregarding choice of law rules. If a dispute cannot be settled by negotiation between parties, it will be settled by the ordinary courts in that country.
- 5. Attachments**
The following attachments are part of this agreement

Attachment A: Recipient’s request for support (application form, letter or email), with detailed program plan, timeline and budget

6. Agreed to and Accepted by:

Date: 10 december 2024

Date: 10 December 2024

On behalf of Recipient:

On behalf of Novo Nordisk:

DocuSigned by:

21B22353305441A...

Signed by:

491905A0B5CF1437...

Name: Claus Richter

Name: Tina Damgaard

Title: Administerende direktør

Title: Medical Manager

Appendix A: Recipient's Request for Support1. Copy of the Recipient's grant request

12. november 2024



Til
CTIK, Christian Klyver Tikkanen
Novo Nordisk Danmark A/S

Ansøgning om støtte til videreudvikling af diabetestest.nu

I samarbejde med IQVIA har Diabetesforeningen udviklet Diabetestest.nu, en offentlig platform, der formidler nationale statistikker om diabetespopulationen i Danmark. Løsningen blev succesfuldt lanceret i april 2023, og siden lanceringen har Diabetesforeningen modtaget feedback fra brugere, ligesom foreningens egne medarbejdere har gjort værdifulde erfaringer med brugen af platformen. Denne feedback har resulteret i et ønske om ændringer til funktionalitet for at forbedre brugeroplevelsen. Diabetesforeningen ønsker at videreudvikle diabetestest.nu med følgende indikatorer og funktioner, der bla. gør det lettere at følge, hvor mange med type 2-diabetes, der er i organbeskyttende behandling:

- En ny indikator om kronisk nyresygdom, CKD
- En ny indikator om både CKD og hjertekarsygdom nogensinde, plus CKD og/eller CVD
- Split indikator GLP1/SGLT2 med erkendt hjerte-kar-sygdom i tre: 1) GLP1 og med erkendt hjerte-kar-sygdom; 2) SGLT2 og med erkendt hjerte-kar-sygdom 3) GLP1/SGLT2 med erkendt hjerte-kar-sygdom OBS! Ikke MECE
- Split indikator GLP1/SGLT2 med erkendt Nyresygdom i tre: 1) GLP1 og med erkendt nyresygdom; 2) SGLT2 og med erkendt nyresygdom 3) GLP1/SGLT2 med erkendt Nyresygdom OBS! Ikke MECE

De to ovenstående kategorier skal desuden ændres til at vises som andel af hhv CVD og CKD sygdom.

Desuden følgende opdateringer:

- Fjerne hjerteflimmer fra hjertekarsygdom-definitionen
- En ny indikator HbA1c < 53 mmol/mol
- En ny indikator om øjenkontrol
- Et nyt filter om brug af kontinuerlig glukosemonitorering,
- Ændre tidsrapportering for alle indikatorer på nær dem under Test udført fra inden for 15 mdr. før udgangen af det pågældende kvartal til inden for 12 mdr. før udgangen af det pågældende kvartal

Stationsparken 24, st. tv.
2600 Glostrup

Telefon 66 12 90 06

Fax 65 91 49 08
info@diabetes.dk
www.diabetes.dk

CVR-nr. DK-35 23 15 28

- Udvikling af en log med informationen om sidens dataopdateringer.
- Mulighed for at vise gennemsnit af de valgte kommuner. Så man kan vælge de kommuner, der er i et bestemt hospitalsområde, og se gennemsnittet.

Arbejdet starter **1. december 2024** og afsluttes i Q1 2025, således at ændringerne vil træde i kraft ved den planlagte dataopdatering **1. april 2025**.

Diabetesforeningen har modtaget et tilbud fra IQVIA på opgaven på DKK 278.365 + moms. Tilbuddet bygger på den eksisterende kontrakt vedrørende udvikling og drift af Diabetestest.nu, og der vil derfor ikke være yderligere omkostninger for Diabetesforeningen i forhold til licens eller drift. Udgifterne relaterer sig alene til den ønskede udvikling af ny funktionalitet.

Desuden vil Diabetesforeningen bidrage med 0.2 FTE i udviklingen.

Diabetesforeningen søger Novo Nordisk Danmark A/S om et sponsorat til hjælp til finansiering af projektet på DKK 200.000 + moms.

Med venlig hilsen



Tanja Thybo

Tlf.: +45 41 91 88 11
tth@diabetes.dk

